Atherosclerosis can be immunomodulated as demonstrated in animal experiments where immunization with oxidationrelated forms of LDL led to amelioration of atherosclerosis, 10 whereas if HSP 60/65 was used, the opposite occurred. 11 Many of the biological effects of oxLDL and modified forms of LDL are exerted through platelet-activating factor-like lipids and lysophosphatidylcholine (LPC). 12, 13 We recently demonstrated that annexin A5 (ANXA5), a plasma protein with antithrombotic properties, reduces inflammation and improves vascular function in apolipoprotein E −/− mice 14 and inhibit LPC-induced inflammatory effects. 15 Using as a model of LDL modification phospholipolysis by the secretory phospholipase A2 (sPLA2) group X, 16 we report here that this modified form of LDL (LDLx) but not native LDL promote T-cell activation through dendritic cells (DCs) and that HSP may play a role in this activation. ANXA5 inhibits these effects. The implications of these findings are discussed.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results oxLDL But Not LDL Induced DC-Mediated T-Cell Proliferation
First, we tested the effects on T-cell activation as determined by proliferation after stimulation with oxLDL-and LDL-treated DCs. LDL had no effect on T-cell proliferation, whereas oxLDL had stimulatory effect in cells from blood ( Figure 
LDLx-Induced Maturation of DCs
We investigated the effect of LDLx on the activation of human DCs. To avoid effects of serum lipoproteins, cells were differentiated from human peripheral blood monocytes in a lipoprotein-free culture medium. Cells had a typical phenotype of immature DCs at day 6, as defined by high CD1a and low CD14 expression (data not shown). LDLx or control LDL was added in the cell culture at day 5 for 24 hours. Control LDL did not induce significant modification in the expression of the analyzed surface markers as compared with control immature DCs. Interestingly, LDLx treatment increased the expression of HLA-DR, CD86, CD83, and CD40 ( Figure 1A) . These results indicate that LDLx induces a phenotypic maturation of DCs in vitro in consistence with Atout et al. 17 CCR2 plays a critical role in DC maturation, and CX3CR1 promotes proper development of myeloid precursors into DCs. LDLx induced the upregulation of CCR2 and CX3CR1.
To characterize the effect of LDLx on DC function, we analyzed the production of cytokines and chemokines from DCs ( Figure 1B ). LDLx induced an increased secretion of TNFα (192±29 and 12±7 pg/mL, respectively, n=6; P<0.01) and interleukin (IL)-1β (263±78 and 37±12 pg/mL, respectively, n=6; P<0.01) compared with LDL stimulation. Low quantity of IL-10 could be detected in supernatants of LDL-or LDLxtreated DCs and immature DCs (41±13 and 32±27 pg/mL, and 22±17 pg/mL, respectively). Low-density lipoprotein modified by human group X-secreted phospholipase A2 (LDLx) induced maturation of dendritic cell (DC). A, The expression of CD86, HLA-DR, CD83, CD40, CCR2, and CX3CR1 was analyzed by flow cytometry at day 6 after a 24-hour treatment with 20 μg/mL low-density lipoprotein (LDL) or LDLx, or 20 μg/mL LDLx+10 μg/mL annexin A5 (ANXA5). A representative of 6 independent experiments is shown. B, Cytokine production tested by ELISA. DC supernatants were collected at day 6 after a 24-hour treatment with 20 μg/mL LDL, 20 μg/mL LDLx, or 20 μg/mL LDLx+10 μg/mL ANXA5. Results represent the mean concentration±SEM of 6 independent experiments. **P<0.01, DC+LDLx vs DC+LDL and DC+LDLx+ANXA5.
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LDLx-Treated DC-Stimulated T-Cell Activation
As mature DCs are of major importance for stimulation of naive T cells, we compared DCs treated with LDLx with DCs, which were treated with LDL, in DC-T cell coculture experiments. We demonstrate that LDLx-treated DCs stimulate T-cell proliferation (Figure 2A ), thus addition of LDLx during the late stage of monocyte differentiation gave rise directly to mature DCs supporting autologous T-cell stimulation.
To study to what extent the inflammatory mediators LDLx polarizes Th-cell development, we analyzed the cytokines secreted by autologous naive T cells in the DC-T-cell cultures. In the cocultures, LDLx-treated DCs induced the release of TGF-α (52±19 pg/mL) and IL-6 (563±179 pg/mL) ( Figure 2B ).
T cell stimulated with LDLx-treated cells produced interferon (IFN)-γ, whereas no significant IL-4 could be detected. Interestingly, small proportion of T cells produced IL-17 ( Figure 2C ). This indicated that LDLx may instruct DC to initiate both Th1 and Th17 polarization.
ANXA5 Abrogated DC Maturation and T-Cell Activation Induced by LDLx
In the presence of ANXA5, the upregulation of CD86, HLA-DR in LDLx-treated DC was abrogated, interestingly, the upregulation of CCR2 and CX3CR1 was sustained ( Figure 1A ). In contrast to LDLx treated only with DC cultures, ANXA5 inhibited the production of IL-1β and TNF-α but increased substantially IL-10 secretion in the DC cultures ( Figure 1B ). Subsequently, T-cell proliferation induced by DC−(LDLx+ANXA5) was significantly reduced compared with that of T cells stimulated with DC−LDLx (Figure 2A ). In the T-cell-DC cocultures, DC−(LDLx+ANXA5) potentiated TGF-β but diminished IL-6 production ( Figure 2B ). Figure 2C ).
ANXA5 Induced the Differentiation of IL-10-Producing T Cells
There were 1.2±0.7% CD4 + CD25 high regulatory T cells in CD4 + CD45RO − CD45RA + cell populations. The percentage of CD4 + CD25 high regulatory T cells was 2.8±1.0%, 2.4±0.8%, and 10.8±2.1% (n=6; P<0.01), respectively after cocultured with DC (LDL), DC (LDLx), or DC (LDLx+ANXA5) ( Figure  III 
IL-10 Producing T Cells Suppressed Primary T-Cell Activation
Naive CD4 + T cells were stimulated with autologous DC−(LDLx+ANXA5). After 13 days culture, T [DC−(LDLx+ANXA5)] cells were tested for their ability to suppress autologous CD4 + T cells activated with mature DCs. Proliferation of naive CD4 + T cells stimulated with mature DCs were significantly reduced by addition of T [DC−(LDLx+ANXA5)] cells at 1:1 ratio ( Figure 3A ). Thus T cells generated with DC−(LDLx+AnxA5) suppress primary T-cell responses. IL-10 and TGF-β could play a role in mediating these effects because proliferation was increased by the addition of neutralizing anti-IL-10R and anti-TGF-β mAbs ( Figure 3B ). In addition, T [DC−(LDLx+ANXA5)] cells require cell-cell contact for their suppressive activity because suppression of T cells was observed in experiments performed using transwell chambers ( Figure 3C ). Overall, these data indicate that T cells generated by DC−(LDLx+ANXA5) stimulation are functionally equivalent to Tr1 cells.
Binding of ANXA5 to LDLx
To test potential protective mechanisms of ANXA5, LDL, and LDLx (50 μg/mL) were coated on ELISA plates overnight before different concentrations of ANXA5 (0, 0.3, 0.6, 1.2, 2.5, 5, 10, and 20 μg/mL) were added to plates. Results indicate that ANXA5 could bind to LDLx but not to LDL ( Figure 4 ).
HSPs Are Involved in the LDLx-Treated DC-T-Cell Interactions
Expression of HSP60 and 90 was upregulated but that of HSP27 was downregulated in LDLx-treated DCs. ANXA5 abolished the upregulation of HSP60 and 90, whereas substantially upregulated the HSP27 expression ( Figure 5A ). HSP70 expression was not changed significantly in the LDLx-treated DCs, and ANXA5 did not influence its expression. Expression of both TLR2 and TLR4 were upregulated in LDLx-treated DCs, whereas ANXA5 limited the upregulation ( Figure 5B ).
HSP Inhibition Abrogated the Effect of LDLx on DCs and the Subsequent T-Cell Proliferation
We then downregulated HSP by lentiviral-expressed shRNA. Both HSP60 and 90 expression were strikingly downregulated ( Figure 6A ); 17-DMAG, a specific HSP90 inhibitor was administered as control. In comparison with the mock treatment, inhibition of HSP60 and 90 decreased considerably the production of TNF-α and IL-1β, but increased IL-10 secretion in the DC cultures ( Figure 6B ). In the T-cell-DC cocultures, HSP60 and 90 inhibition sustained TGF-β but diminished IL-6 production ( Figure 6C ). In the subsequent T-cell proliferation assay, inhibition of HSP60 and 90 significantly reduced T-cell proliferation compared with that in mock-treated cultures ( Figure 6D ).
We studied further the human plaque T-cell response to autologous LDLx-treated DCs. Plaque was rinsed intensively with phosphate buffered saline and medium RPMI-1640 to reduce the risk of contamination. Even though we cannot completely rule out blood contamination from these studies, measures were thus taken to decrease this risk, by carefully washing the material from atherosclerotic plaques. T cells were isolated from carotid atherosclerotic plaques, phenotype and activation status of T cells were analyzed by flow cytometry (Figure 7A and 7B ). CD4 T cells and CD8 T cells constituted 54±14% and 37±12% of T cells, respectively. Naive (CD45RA positive) and memory (CD45RO positive) T cells were 19±9% and 71±11%, respectively. We tested the expression of late activation marker CD25, as well as the early activation marker CD69. There were 33±12% and 4±2% of T cells expressing CD25 and CD69, respectively. Overall, the frequency of CD25 and CD69 expressing cells was slightly higher in CD4 T cells, as compared with CD8 T cells. We demonstrated that LDLx-treated DCs, which were generated from peripheral blood monocytes of the same subject, stimulated plaque T-cell proliferation, which was abrogated by ANXA5 ( Figure 7C ). Furthermore, HSP60 or 90 in the LDLxtreated DCs were downregulated by shRNA, which abrogated T-cell proliferation ( Figure 7D ).
Discussion
We here report that oxLDL and LDLx but not native LDL promote T-cell activation through DCs. This finding is in line with and extends our previous findings where we for the first time demonstrated that oxLDL induces T-cell activation 7 and also that LPC-and platelet-activating factor-like lipids are of importance for immune activation by modified forms of LDL. 12, 13 Importantly, this effect on T cells was mediated by DCs from the same donor. DCs are specialized antigen-presenting cells, which may play an important role in the initiation and progression of atherosclerosis. 18 DCs are present in their immature forms within the arterial wall and become activated during atherogenesis. In atherosclerotic lesions in humans, DCs are present both at an early stage 19 and late stage (more DCs in vulnerable plaques). 20 Similar findings have been reported in mice, both at an early stage 21 and late where DCs may promote atherogenesis. 22 Furthermore, DCs and T cells colocalize in plaques, 23 suggesting their participation in cellular immune reactions of importance for disease modulation.
The oxLDL used herein is oxidized by exposure to copper ions, which is not likely to occur in human atherosclerotic lesions, although it is still likely that such oxLDL shares many properties with the modified LDL, which is present in lesions. LPC is a key inflammatory phospholipid in the atherosclerotic lesions and is a major product in the enzymatically modified LDL used in this study. Furthermore, LDLx could have more broad implications in other inflammatory diseases, a possibility supported by evidence of oxLDL present in synovial fluid from RA patients 24 and raised oxLDL-levels in SLE. 25 Even though enzymatically modified LDL was not studied, these findings still give support to a role in other inflammatory conditions as well.
Because enzymatically modified LDL is likely to mimic the in vivo situation, we chose to focus on LDLx, likely to be most physiological, even though not only LDLx but also oxLDLinduced T-cell activation in T cells from plaques, through DC. LDLx but not LDL induced differentiation and activation with increased expression not only of CD86 but also of other markers, including CD83, CD40, HLA-DR, CCR2, and CX3CR1. These findings confirm and extend previous reports 17, 26, 27 and are also in line with our early studies demonstrating that oxLDL can induce monocyte (and endothelial cell) differentiation and activation. 28 PLA2-modified LDL is of major interest because such modification could have broad implications not only for atherosclerosis but also for other inflammatory conditions in general (where T cells also play an important role). 29 However, there are >30 different types of human PLA2 described, and their properties may vary and not all are proinflammatory. 29 The human group X sPLA2 (hGXsPLA2) has interesting properties because it binds with high affinity to zwitterionic phospholipids, especially to phosphatidylcholine, which is a major phospholipid in cell membranes and lipoproteins. 30 Hydrolysis of phosphatidylcholine in LDL by hGX-sPLA2 releases LPC and also arachidonic or oleic acid. 31 Furthermore, hGX-sPLA2 is present in its active form in human atherosclerotic lesions. 32 Owing to these interesting atherosclerosis-relevant properties, we chose to focus on sPLA2GX-modified LDL (LDLx).
Apart from the proinflammatory effects of the sPLA2 hydrolyzed LDL in atherosclerosis in vitro, the mechanisms of PLA2 action in vivo are still poorly understood. 33 Conflicting data exist about the role of PLA2GX in vivo as PLA2GX ( −/− ) mice have shown both pro inflammatory and anti-inflammatory effects. [34] [35] [36] Different mouse strains express different sPLA2s and the possibility that in a knock out setting there is overexpression of another sPLA2 or a cross-talk with intracellular PLA2s exists. However, translation of the results found in mouse models to humans needs to be cautious.
Furthermore, we report that T cells responded to DCs, activated and differentiated by LDLx. T cells were activated to express a mainly proinflammatory profile and developed into Th1 and Th17 cells. In mouse models for atherosclerosis, the role of IL-17 in different stages of atherosclerosis development has been debated with somewhat conflicting data depending on model used. [37] [38] [39] However, in human atherosclerosis, the Th17 phenotype 40 and, in our previous studies, a Th1 type of cytokine profile was dominant in advanced atherosclerotic plaques 1 and in vulnerable plaques. 41 Of note, human plaque rupture (leading to cardiovascular disease) does not seem to be fully mimicked in the published mouse models. 42 T-cell activation caused by enzymatically modified phospholipids could thus play a role not only in atherosclerosis but also in other inflammatory conditions, where the causes of T-cell activation in general are not well characterized.
Another observation is that when T cells activated by LDLxtreated but not LDL-treated DC were cocultured with naive T cells in the presence of matured DC, both types of T cells proliferated. This finding indicates a potential synergy effect, and that in addition to a specific T-cell activation, there may also exist an additional effect caused by cytokine secretion or other effector mechanisms from already activated T cells. In contrast to LDLx and oxLDL, LDL had no effect on DC-mediated T-cell activation. This finding raises important questions. We first reported that oxLDL can activate T cells in previous studies, 7 a finding extended to T-cell clones from atherosclerotic plaques, which recognized oxLDL. 8 Also LDL, at higher concentrations in those studies could promote T-cell activation, and we drew the conclusion that this finding was caused by LDL being modified by coculture in the cell-culture system, a notion supported by other data from our group where a similar cell culture system was used. 43 We have demonstrated that LPC or other proinflammatory phospholipids generated during LDL-oxidation or modification by enzymes mimic the effects of oxLDL. 12, 13, 44 In this study, we have used LDL which is not oxidized, and LDL had no effect in human T-cell activation.
In a recent study, oxLDL had no effect on T-cell activation in a mouse model (apoE −/− ) in contrast to LDL and apoB100, which activated T cells through an MHC class II-dependent mechanism. 45 Mice transgenic for human apoB were used in this study, which did not include human T cells (or DCs). It was concluded that CD4 + T cells recognize epitopes on native ApoB100 protein in this experimental system. Furthermore, this response is associated with clonotypic T-cell receptors, and blocking T-cell receptors-dependent antigen recognition by these T cells protects against atherosclerosis. 45 It is not clear how T cell tolerance to LDL-related antigens develop in this mouse model, and may differ from man.
We here report that downregulation of HSP60 and 90, ameliorates immune reactivity against LDLx by T cells (through DC). Similar results were obtained when HSP-induction was inhibited, indicating that HSP is involved in LDLx (and LPC-) mediated immune reactivity. In a previous article, we demonstrated that oxLDL can induce HSP60. 46 We here confirm and extend this finding.
HSPs, especially HSP60 and 90 have been proposed to play an important role in the initiation but also development of atherosclerosis through their immunogenicity and also through crossreactivity with HSP from microorganisms as bacteria. 11, 47 In line with this notion are findings reporting that there are HSP60 specific T cells in atherosclerosis 9 and our studies herein also demonstrate that HSP play a role in LDLx activation of plaque T cells.
Besides being specific T-cell antigens per se, presented on antigen presented cells, HSP or peptides thereof could promote immune activation by other mechanisms, in a nonmutually exclusive way. HSP being chaperones can form immune complexes with other antigens including tumor antigens, and these can be presented as antigens through classes I or II antigen presenting pathways. 48 Furthermore, HSP can be actively released through exosomes or passively as in cell necrosis. Such HSP could function as endogenous ligands in the extracellular space HSP and activate the innate immune system, through toll-like receptors (TLRs) or by association with ligands as endotoxin. 49 TLRs are potential link between inflammation, infectious disease, and atherosclerosis. HSP as endogenous ligands have also been proposed to react to TLRs. Interestingly, our data shows the expression of both TLR2 and TLR4 were upregulated in LDLx-treated DCs, whereas ANXA5 limited the upregulation. We recently reported that ANXA5, a plasma protein with anticoagulant properties, inhibits atherosclerosis and inflammation and improves endothelial function in a mouse model of atherosclerosis, 14 and that ANXA5 can inhibit proinflammatory effects on monocytes/macrophages and endothelial cells. 15 The underlying mechanism for these beneficial effects is not clear, but our present data indicate that effects on inflammation and T-cell activation could play a role. We here report that ANXA5 not only inhibited T-cell activation including proliferation and production of proinflammatory cytokines but also promoted development of T-regulatory cells. Because these may play an important role as protective cells in chronic inflammation including atherosclerosis, ANXA5 maybe an interesting therapeutic candidate.
There were more CD4 than CD8 T cells in the plaques tested, and, interestingly, the proportion of naive T cells was relatively high, almost 20%. Furthermore, expression of the late activation marker CD25 was relatively high, and seen in a third of tested samples. Clearly, the significance of different T-cell subsets in atherosclerotic plaques deserve further study.
Taken together, our data indicate that LDLx but not LDL activate human T cells through DCs. HSPs, especially HSP60 and 90, play a role in this immune reactivity as T-cell antigens but also through other mechanisms. ANXA5 inhibits these effects and promotes activation of T-regulatory cells. 
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